Clinical trial for HER2-positive BC with brain metastases

Moderators

Open Trials Women's Malignancies Branch, NCI/NIH

Contact: Alexandra Zimmer, MD

alexandra.zimmer@nih.gov

T-DM1 +/- Temozolomide (NCT03190967)

https://www.clinicaltrials.gov/ct2/show/NCT03190967?term=temozolomide&cond=Breast+Cancer&rank=10

Phase 1 dose escalation then randomized Phase 2 with T-DM1 given q3 weeks with oral Temozolomide daily

Patients: HER2-positive BC with brain metastases

Requires: up to 1-3 brains mets, treated up to 6 weeks prior to enrollment with SRS and/or resection

Patients with 4-5brain mets can be evaluated for potential enrollment

No prior WBRT or leptomeningeal disease